Teprotumumab N01 or steroids after eye surgery for thyroid optic nerve damage
Compares teprotumumab N01 with steroids after surgery in dysthyroid optic neuropathy.
Key facts
- Who runs it
- Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- Aug 2026
- Expected to end
- Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Teprotumumab N01
- Intravenous Methylprednisolone (IVMP)
- Record updated
- 19 May 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Able and willing to provide written informed consent
- Age 18 to 65 years
- Clinical diagnosis of thyroid eye disease (TED) with dysthyroid optic neuropathy (DON). Diagnosis of DON must meet both of the following criteria:; Visual dysfunction not explained by other causes, such as decreased best-corrected visual acuity, visual field defect, abnormal color vision, or relative afferent pupillary defect; Imaging evidence of orbital apex crowding, optic nerve compression, or optic nerve stretching
- The study eye meets the criteria for urgent orbital decompression, defined as either of the following:; Poor response after rescue intravenous methylprednisolone for the current dysthyroid optic neuropathy episode, with a cumulative methylprednisolone-equivalent dose of no more than 3.0 g, defined as no improvement or continued deterioration of visual function within 1 to 2 weeks; Contraindication to glucocorticoids or investigator judgment that direct urgent mechanical decompression is required
- Thyroid function is normal or mildly abnormal before enrollment, with free triiodothyronine (FT3) and free thyroxine (FT4) within 50% above or below the normal reference range when possible
- Alanine aminotransferase (ALT) no more than 1.5 times the upper limit of normal, aspartate aminotransferase (AST) no more than 3 times the upper limit of normal, and serum creatinine no more than 1.5 times the upper limit of normal
- For participants with diabetes mellitus, hemoglobin A1c (HbA1c) less than 9.0% and stable antidiabetic treatment within 60 days before enrollment
- For women of childbearing potential, a pregnancy test must be negative before enrollment
- Participants of reproductive potential agree to use effective contraception during the study and for 90 days after the last dose of study treatment
- Able and willing to comply with study treatment and follow-up procedures
Who cannot take part
- Orbital decompression surgery within 6 months before screening
- Systemic glucocorticoid treatment for non-thyroid eye disease within 3 months before screening with cumulative methylprednisolone-equivalent dose of 1.0 g or greater
- Tocilizumab or other systemic immunosuppressive treatment within 3 months before screening, or rituximab within 6 months before screening
- Orbital radiotherapy within 3 months before screening
- Previous treatment with teprotumumab
- Other ocular diseases that may significantly affect visual function assessment, including glaucomatous optic neuropathy, macular disease, severe cataract, or non-thyroid eye disease optic neuropathy
- History of definite inner ear disease or clinically significant hearing impairment
- Severe cardiovascular disease
- Severe hepatic or renal disease
- Active infection or clinically significant infectious disease, including active hepatitis, HIV infection, syphilis, or active tuberculosis
- Active gastrointestinal ulcer
- History of malignancy judged by the investigator to be unsuitable for enrollment
- Known allergy to monoclonal antibodies, methylprednisolone, or any study drug excipient
- Uncontrolled diabetes mellitus or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study
- Clinically significant abnormal blood test results, including white blood cell count less than 4.0 × 10\^9/L, platelet count less than 80 × 10\^9/L, hemoglobin less than 110 g/L in males or less than 100 g/L in females
- Bilateral dysthyroid optic neuropathy requiring urgent bilateral orbital decompression at baseline
- Cumulative preoperative methylprednisolone-equivalent dose greater than 3.0 g for the current dysthyroid optic neuropathy episode
- Irreversible optic nerve damage in the study eye with very low potential for visual recovery, as judged by the investigator
- Pregnancy or breastfeeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).
The 2 groups in the trial
- Postoperative Sequential Teprotumumab N01Treatment being tested
Participants in this arm will undergo urgent orbital decompression and then receive postoperative sequential Teprotumumab N01.
Treatment: Teprotumumab N01
- Postoperative Sequential Intravenous MethylprednisoloneExisting treatment, for comparison
Participants in this arm will undergo urgent orbital decompression and then receive postoperative sequential intravenous methylprednisolone.
Treatment: Intravenous Methylprednisolone (IVMP)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-Center, Prospective, Randomized, Open-Label, Parallel-Group Study Comparing Sequential Teprotumumab N01 With Intravenous Methylprednisolone After Urgent Orbital Decompression in Patients With Dysthyroid Optic Neuropathy
- Plain-language title
- Teprotumumab N01 or steroids after eye surgery for thyroid optic nerve damageGenerated from the registry record. The registry title is the official one.
- Criteria questions
- Built from NCT07594912, who can take part
- Record updated
- 19 May 2026